MRSA nursing: assessment, interventions, and infection control

MRSA — methicillin-resistant Staphylococcus aureus — is one of the most clinically significant drug-resistant pathogens nurses encounter across every care setting. In the United States, MRSA causes more than 80,000 invasive infections and approximately 11,000 deaths annually, according to the CDC. It colonizes the nares, skin, and mucous membranes of roughly 2% of the general population and up to 30–50% of healthcare workers on some units. For nursing students, MRSA is a top NCLEX topic bridging infection control, pharmacology, wound management, and patient education. Recognizing MRSA, implementing contact precautions correctly, monitoring vancomycin therapy, and educating patients before discharge are core nursing responsibilities regardless of clinical specialty.

This reference covers pathophysiology, clinical presentation, diagnostic workup, infection control, treatment with drug-specific nursing implications, wound care, patient education, complications, and six NCLEX-style practice questions. Use alongside the sepsis nursing reference for bacteremia and septic shock content, the wound assessment guide for systematic wound evaluation, the osteomyelitis nursing reference for bone and joint MRSA infections, and the nursing lab values cheat sheet for vancomycin trough interpretation and inflammatory markers.

Fast-scan summary

Pathophysiology

Staphylococcus aureus overview

Staphylococcus aureus is a gram-positive, catalase-positive, coagulase-positive coccus that colonizes the anterior nares, axillae, perineum, and skin folds of healthy individuals without causing disease. It becomes pathogenic when it breaches skin or mucosal barriers — through surgical incisions, IV catheter insertion sites, traumatic wounds, or hematogenous spread — triggering a spectrum of infections from superficial furuncles to life-threatening bacteremia, endocarditis, and necrotizing pneumonia.

mecA gene and PBP2a: the resistance mechanism

The defining feature of MRSA is the mecA gene, which is carried on a mobile genetic element called staphylococcal cassette chromosome mec (SCCmec). The mecA gene encodes penicillin-binding protein 2a (PBP2a), a transpeptidase with markedly reduced affinity for virtually all beta-lactam antibiotics, including penicillins, cephalosporins, carbapenems, and monobactams. Because beta-lactams work by binding to penicillin-binding proteins and inhibiting cell wall synthesis, PBP2a renders the entire drug class ineffective. This is not an enzyme-based resistance (like beta-lactamase production) — it is structural. No beta-lactam can adequately inhibit PBP2a at clinically achievable concentrations.

This single chromosomal change explains why an MRSA-positive patient requires vancomycin or alternative non-beta-lactam therapy rather than standard first-line agents like nafcillin or cefazolin that would otherwise cover methicillin-susceptible S. aureus (MSSA).

HA-MRSA vs CA-MRSA

MRSA is broadly divided into two epidemiological categories based on where acquisition occurred:

Healthcare-associated MRSA (HA-MRSA) typically causes infections in patients hospitalized for ≥48 hours, in long-term care residents, or in individuals with recent surgery, dialysis, IV catheter use, or indwelling devices. HA-MRSA strains commonly carry large, diverse SCCmec elements (types I–III) and tend to be resistant to multiple antibiotic classes in addition to beta-lactams.

Community-associated MRSA (CA-MRSA) occurs in outpatients without healthcare exposure within the previous year. The predominant US strain is USA300, which carries SCCmec type IV and the gene encoding Panton-Valentine Leukocidin (PVL), a pore-forming cytotoxin that destroys leukocytes and is strongly associated with necrotizing skin and soft tissue infections and necrotizing pneumonia. CA-MRSA tends to be susceptible to more non-beta-lactam antibiotics than HA-MRSA strains, which partly explains why oral agents like TMP-SMX remain effective for uncomplicated community-acquired skin infections.

Biofilm formation

S. aureus produces a polysaccharide biofilm matrix that adheres to prosthetic devices, catheters, and bone. Biofilm dramatically reduces antibiotic penetration, increases tolerance to host immune responses, and enables chronic, relapsing infection — a key reason MRSA prosthetic joint infections and MRSA osteomyelitis are so difficult to eradicate without surgical hardware removal.

Common infection sites

MRSA causes infection across virtually every organ system. The most clinically significant sites are:

• Skin and soft tissue: Furuncles, carbuncles, abscesses, cellulitis, necrotizing fasciitis (especially USA300)
• Bloodstream: MRSA bacteremia, which carries 20–30% in-hospital mortality and frequently seeds secondary sites
• Endocardium: Infective endocarditis — right-sided in IV drug users, left-sided in healthcare-associated bacteremia
• Bone and joint: Osteomyelitis, septic arthritis — see the osteomyelitis nursing reference for full detail
• Lung: Pneumonia — particularly post-influenza necrotizing pneumonia with CA-MRSA/USA300; hospital-acquired pneumonia and ventilator-associated pneumonia with HA-MRSA
• CNS: Meningitis, epidural abscess (less common)

Clinical presentation

Signs and symptoms vary significantly by infection site, but MRSA should be suspected in any wound that fails to respond to standard beta-lactam antibiotics, in any hospitalized patient who develops new signs of infection, and in community patients who develop rapidly progressing skin infections.

General signs: Fever, elevated WBC with left shift, elevated inflammatory markers (CRP, ESR), tachycardia. In severe infections: hypotension, altered mental status, signs of sepsis (see sepsis nursing reference for full sepsis recognition criteria).

Skin and soft tissue MRSA: Warm, erythematous, indurated lesion; central fluctuance or pustular center suggesting abscess; surrounding cellulitis; satellite lesions possible with USA300; rapid progression distinguishes MRSA from typical streptococcal cellulitis.

MRSA bacteremia: Fever, chills, rigors; bacteremia without obvious source in a patient with IV access should prompt central line removal and blood culture workup. New cardiac murmur, embolic phenomena (Janeway lesions, Osler nodes, splinter hemorrhages), or signs of metastatic infection suggest endocarditis.

MRSA pneumonia: Productive cough, hemoptysis, high fever, rapid consolidation; chest imaging may show cavitation (necrotizing pneumonia), particularly with USA300/PVL-positive strains following influenza.

HA-MRSA vs CA-MRSA: clinical comparison

Diagnostic workup

Accurate microbiological diagnosis is essential for confirming MRSA, guiding antibiotic selection, and directing infection control measures. Culture and sensitivity results must drive treatment decisions — do not rely on clinical impression alone to assume MRSA vs MSSA.

Infection control and isolation

Contact precautions are the cornerstone of preventing MRSA transmission in healthcare settings. The key principle — frequently misunderstood on NCLEX and in clinical practice — is that contact precautions require gown and gloves on room entry, not only when providing direct patient care or touching the patient. MRSA survives on dry surfaces (bed rails, call buttons, IV poles, blood pressure cuffs, keyboards) for hours to days. Any contact with the environment of an MRSA patient is a transmission risk.

Elements of contact precautions

Gown and gloves: Don before entering the room. Remove before leaving — in the room, not in the hallway. Perform hand hygiene immediately after removal. The sequence matters: gloves off first (they are the most contaminated), then gown, then hand hygiene before touching any clean surface or leaving the room.

Private room: MRSA patients should be placed in a private room with the door closed. If private rooms are unavailable, cohort MRSA patients together (same organism, same precaution level). Do not cohort MRSA with patients who have a different resistant organism.

Dedicated equipment: Use dedicated stethoscopes, blood pressure cuffs, thermometers, and other equipment for the patient’s room. If shared equipment is unavoidable, disinfect thoroughly with an EPA-registered disinfectant effective against MRSA before use on another patient.

Hand hygiene: Alcohol-based hand rub (ABHR) is effective against MRSA and is acceptable in most circumstances — MRSA is not a spore-forming organism, and ABHR is adequate for non-spore-forming bacteria. Soap and water is preferred when hands are visibly soiled or when transitioning from a contact-precautions environment with potential heavy contamination. The CDC emphasizes that ABHR is convenient and promotes compliance; the priority is performing hand hygiene at all five moments (before patient contact, before aseptic task, after body fluid exposure, after patient contact, after contact with patient surroundings).

Transport: Minimize transport. When transport is necessary (procedures, imaging), notify the receiving department in advance; the patient should wear a gown; MRSA status must be communicated to all providers at handoff.

Signage: Contact precaution signs on the door must be visible, legible, and include clear instructions for visitors. Avoid signage that stigmatizes the patient — the sign should direct action (PPE required), not label the individual.

Patient and visitor education

Visitors must receive education before entering the room. Key teaching points:

• Why contact precautions are in place (protect others and themselves, not punishment)
• How to don and doff gown and gloves correctly
• Hand hygiene on exit
• Do not bring in outside items (food, flowers, personal items) without checking with the nurse
• Do not visit other patients on the unit after visiting an MRSA patient without first removing PPE and performing hand hygiene

When to discontinue contact precautions

The most widely used standard for discontinuing MRSA contact precautions is three consecutive negative MRSA cultures from original site(s) of colonization or infection, obtained at least 24 hours apart, while the patient is not receiving anti-MRSA antibiotics. Some institutions use two negative cultures. The decision to discontinue precautions is made by infection control in coordination with the treating team — nurses should not independently discontinue precautions based on clinical impression alone.

Decolonization (see Treatment section below) does not automatically mean precautions can be discontinued; cultures must confirm clearance.

Treatment

MRSA requires non-beta-lactam therapy. Antibiotic selection depends on infection site, severity, and patient-specific factors including renal function, allergy history, and prior antibiotic exposure.

Vancomycin

Vancomycin is a glycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors — a different binding site than beta-lactams. It remains the first-line IV agent for serious MRSA infections including bacteremia, endocarditis, osteomyelitis, and pneumonia.

Dosing and monitoring: The traditional target vancomycin trough is 10–20 mcg/mL, with higher troughs (15–20 mcg/mL) recommended for serious infections such as bacteremia, endocarditis, and meningitis. However, the 2020 ASHP/IDSA/SIDP consensus guidelines now recommend AUC/MIC-guided dosing as the preferred monitoring strategy. The target AUC is 400–600 mg·h/L (for an organism with MIC ≤1 mcg/mL). AUC-guided monitoring reduces nephrotoxicity compared to aggressive trough-only targeting while maintaining efficacy.

For nursing practice and NCLEX, the key numbers to know are:

• Therapeutic trough: 10–20 mcg/mL
• Subtherapeutic trough (<10 mcg/mL): risk of treatment failure and resistance emergence
• Supratherapeutic trough (>20 mcg/mL): nephrotoxicity risk rises significantly

Nursing implications for vancomycin:

• Obtain trough level 30 minutes before the fourth dose (steady state) — or per pharmacy protocol
• Never push IV vancomycin — must be infused over at least 60 minutes (large doses over 90–120 minutes) to prevent Red Man Syndrome (flushing, erythema, pruritis of face/neck/upper torso — an infusion reaction, not a true allergy)
• Monitor serum creatinine and BUN every 48–72 hours during therapy
• Monitor urine output — oliguria may precede serum creatinine rise by 12–24 hours
• Report rising creatinine, troughs above 20 mcg/mL, or signs of ototoxicity (tinnitus, hearing change) to prescriber immediately
• Ensure adequate hydration; avoid concurrent nephrotoxins (NSAIDs, aminoglycosides, contrast agents) when possible
• If patient requires IV line access, monitor IV site integrity and PICC line management closely — vancomycin is irritating to peripheral veins; central access is preferred for prolonged courses

Daptomycin

Daptomycin is a cyclic lipopeptide that disrupts bacterial cell membrane function. It is effective for MRSA bacteremia, endocarditis, and skin/soft tissue infections.

Critical contraindication: daptomycin must NOT be used for MRSA pneumonia. Pulmonary surfactant inactivates daptomycin by binding the drug before it can reach bacteria in the lung parenchyma. This is one of the most frequently tested pharmacology points for MRSA on NCLEX and in clinical practice. A patient with MRSA pneumonia who receives daptomycin will have treatment failure — use vancomycin or linezolid instead.

Nursing implications for daptomycin:

• Monitor CPK (creatine phosphokinase) weekly — daptomycin causes myopathy and rhabdomyolysis, especially with concurrent statin use; report muscle pain, weakness, or dark urine
• Hold statins during daptomycin therapy when possible
• Once-daily dosing — renal dose adjustment required for CrCl <30 mL/min

Linezolid

Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA subunit. It has excellent oral bioavailability (approximately 100%), making it the preferred oral agent for serious MRSA infections when IV-to-oral transition is warranted. It is effective for MRSA pneumonia (unlike daptomycin).

Nursing implications for linezolid:

• Serotonin syndrome risk: Linezolid is a weak monoamine oxidase inhibitor (MAOI). Concurrent use with SSRIs, SNRIs, TCAs, meperidine, tramadol, or other serotonergic agents can precipitate serotonin syndrome — assess medication list before administration, report interactions to prescriber
• Thrombocytopenia: CBC should be checked weekly; platelet count <100,000/mcL requires dose reassessment; platelet count <50,000/mcL generally warrants discontinuation
• Duration limit: Risk of adverse effects (myelosuppression, peripheral neuropathy, optic neuropathy) increases significantly beyond 28 days of use
• Avoid tyramine-rich foods (aged cheese, cured meats, fermented products) during oral therapy — MAOI activity can cause hypertensive crisis

TMP-SMX (trimethoprim-sulfamethoxazole)

TMP-SMX inhibits bacterial folate synthesis at two sequential steps. It is first-line oral therapy for uncomplicated CA-MRSA skin and soft tissue infections (furuncles, abscesses, cellulitis without systemic signs) when cultures confirm susceptibility. Not appropriate for invasive infections, bacteremia, or endocarditis.

Nursing implications: Monitor for sulfa allergy reactions (rash, fever, Stevens-Johnson syndrome); ensure adequate hydration to reduce crystalluria risk; contraindicated in pregnancy (especially third trimester) and in patients with sulfonamide hypersensitivity.

Clindamycin and the D-zone test

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis. It is used for CA-MRSA skin and soft tissue infections in some patients, but requires confirmation that inducible MLSB resistance is absent before use.

Some MRSA strains carry the erm gene, which encodes methylase enzymes that confer macrolide-lincosamide-streptogramin B (MLSB) resistance. In some strains this resistance is inducible — the bacteria appear susceptible to clindamycin on standard disk diffusion testing but will develop clinical resistance when exposed to clindamycin in the presence of a macrolide inducer. The D-zone test (double-disk diffusion test) detects this inducible resistance: a clindamycin disk is placed adjacent to an erythromycin disk on an agar plate. If the inhibition zone around the clindamycin disk is blunted on the side facing the erythromycin disk (creating a D-shaped zone rather than a round zone), inducible MLSB resistance is present and clindamycin should NOT be used. A round inhibition zone indicates true susceptibility.

Nurses do not perform the D-zone test, but must understand the concept to explain to patients and families why clindamycin was changed or why the lab report says “susceptible-inducible” rather than simply “susceptible.”

Decolonization protocol

Decolonization reduces MRSA carriage and decreases risk of surgical site infection and recurrent community transmission. The standard protocol is:

• Mupirocin 2% nasal ointment: Apply a small amount to each nostril with a cotton swab or fingertip, BID × 5 days. Gently press nostrils together after application to distribute. Do not use intranasal mupirocin more than twice per year — resistance emergence has been documented with frequent use.
• Chlorhexidine gluconate (CHG) 4% body wash: Bathe the entire body from neck to toes (avoid eyes and mucous membranes) daily × 5 days. Allow contact time of 2–3 minutes before rinsing. Patients should use clean cloths or hands, not washcloths that may harbor organisms.

Decolonization is commonly used preoperatively in MRSA-positive patients, in recurrent CA-MRSA skin infections, and in outbreak control. Follow-up cultures confirm clearance.

Nursing interventions summary

Patient education

Patient and family education for MRSA should begin at the time of diagnosis and continue through discharge. The goal is to prevent household transmission, reduce recurrence risk, and ensure antibiotic adherence.

While hospitalized: Explain what MRSA is in plain language (“a type of bacteria that has become resistant to many antibiotics — the isolation precautions protect other patients, not just you”). Teach family members and visitors how to put on and remove gown and gloves before they enter and exit. Reinforce that MRSA is common and manageable, not a sign of poor hygiene or negligence.

Antibiotic adherence: Complete the full antibiotic course even if the wound looks better or the patient feels well. Stopping early risks relapse and resistance emergence. If oral antibiotics cause nausea, take with food. Report any new symptoms — rash, diarrhea, fever — to a provider rather than stopping the medication.

Home wound care: Change dressings using clean technique (wash hands before and after); dispose of used dressings directly into a plastic bag; do not reuse dressings or instruments; keep wound covered until healed. Contact the provider if the wound increases in size, develops new drainage, becomes more painful, or is accompanied by fever.

Preventing household spread:

• Do not share towels, razors, washcloths, or bar soap
• Wash clothing, towels, and bedding in hot water and dry on high heat after wound care
• Clean bathroom surfaces (toilet seat, sink, handles) with a household disinfectant after wound care
• Household members with skin sores, cuts, or rashes should seek evaluation

When to call: Fever above 38.5°C (101.3°F), spreading redness or red streaks from wound, new swelling, pus or foul-smelling drainage, worsening pain, nausea or vomiting preventing oral antibiotic intake.

Decolonization at home (if prescribed): Walk through the mupirocin and chlorhexidine protocol step by step. Confirm the patient can accurately demonstrate how to apply nasal ointment. Explain that decolonization reduces but does not guarantee elimination of MRSA carriage and that follow-up cultures will confirm results.

Complications and monitoring

Untreated or inadequately treated MRSA infection carries substantial morbidity and mortality. Nurses must recognize early signs of complications to escalate care promptly.

NCLEX-style practice questions

Question 1

A nurse is caring for a patient admitted with a wound culture positive for MRSA. Which action should the nurse take first when preparing to enter the patient’s room?

A. Apply a surgical mask at the doorway B. Don a gown and gloves before entering the room C. Apply gloves only if planning to perform a wound dressing change D. Wash hands with soap and water after entering the room

Correct answer: B

Rationale: Contact precautions require the nurse to don a gown and gloves before entering the room — not only when providing direct care or touching the patient. MRSA contaminates environmental surfaces (bed rails, call lights, IV poles) and can be transmitted by any contact with the patient environment, not just the patient’s skin. Answer A is incorrect — a surgical mask is not required for standard MRSA contact precautions unless droplet or airborne precautions are also indicated. Answer C is incorrect — gloves alone are insufficient and must be accompanied by a gown; wearing PPE only for the dressing change but not on room entry violates contact precaution standards. Answer D is incorrect — hand hygiene should occur before and after entering, but it is not the first action required on entry; gown and gloves must be donned first.

Question 2

A nurse is reviewing a patient’s vancomycin trough level drawn 30 minutes before the fourth scheduled dose. The result is 8 mcg/mL. What is the priority nursing action?

A. Administer the next dose as scheduled — the level is within the therapeutic range B. Hold the next dose and notify the provider that the trough is supratherapeutic C. Notify the provider that the trough is subtherapeutic and anticipate a dose increase D. Redraw the level in 2 hours before taking any action

Correct answer: C

Rationale: A vancomycin trough of 8 mcg/mL is subtherapeutic — the therapeutic range is 10–20 mcg/mL (with 15–20 mcg/mL often targeted for serious infections). Subtherapeutic troughs increase the risk of treatment failure and emergence of vancomycin-resistant S. aureus (VRSA). The nurse must notify the provider so the dose or interval can be adjusted. Answer A is incorrect — 8 mcg/mL is below the therapeutic trough range. Answer B is incorrect — the trough is subtherapeutic, not supratherapeutic; holding the dose would worsen the deficit. Answer D is incorrect — waiting for a recheck without provider notification delays necessary adjustment. The fourth-dose trough (or steady-state trough per protocol) is the appropriate time to evaluate and adjust dosing.

Question 3

A patient with MRSA pneumonia is receiving vancomycin but continues to deteriorate. The provider decides to switch to daptomycin. Which response by the nurse is most appropriate?

A. Administer daptomycin as ordered — it is a common alternative for MRSA B. Question the order — daptomycin is contraindicated for pulmonary MRSA infections C. Administer daptomycin and monitor CPK levels every 48 hours D. Request clarification about the vancomycin dose before switching agents

Correct answer: B

Rationale: Daptomycin is contraindicated for pulmonary infections because pulmonary surfactant binds and inactivates daptomycin before it can reach bacteria in the lung parenchyma, resulting in treatment failure. The nurse has a professional responsibility to question orders that are clinically unsafe. Nurses are patient advocates — catching a contraindicated drug order is within scope of nursing practice and the standard of care. The appropriate alternatives for MRSA pneumonia are vancomycin or linezolid. Answer A is incorrect — daptomycin is effective for MRSA bacteremia and skin infections but is specifically contraindicated in pneumonia. Answer C is incorrect — proceeding with an unsafe order and monitoring is insufficient. Answer D is incorrect — while understanding vancomycin dosing is appropriate, it does not address the immediate contraindication with daptomycin.

Question 4

A nurse is teaching a patient who was admitted with a recurrent MRSA skin abscess. The provider has prescribed a decolonization protocol. Which instruction should the nurse include?

A. Apply mupirocin nasal ointment to both nostrils once daily for two weeks B. Apply mupirocin nasal ointment to both nostrils twice daily for five days and bathe with chlorhexidine 4% body wash daily for five days C. Use chlorhexidine body wash once daily until the next follow-up appointment D. Apply mupirocin to the wound itself twice daily for five days

Correct answer: B

Rationale: The standard MRSA decolonization protocol is mupirocin 2% nasal ointment BID × 5 days combined with chlorhexidine gluconate 4% body wash daily × 5 days. The nares are the primary MRSA reservoir in colonized individuals, which is why intranasal mupirocin is the mainstay of decolonization. Answer A is incorrect — the correct frequency is BID (not once daily) and the duration is 5 days (not two weeks; prolonged use increases resistance risk). Answer C is incorrect — chlorhexidine alone without mupirocin is insufficient for decolonization. Answer D is incorrect — mupirocin for decolonization is applied intranasally to reduce carriage from the nares, not applied to the wound.

Question 5

A nurse is reviewing the microbiology report for a patient with a soft tissue abscess. The culture shows MRSA with the sensitivity panel noting clindamycin “susceptible-inducible” (D-zone test positive). What does this result mean for the patient’s treatment?

A. Clindamycin is the drug of choice because the organism is susceptible B. Clindamycin should not be used — the positive D-zone test indicates inducible resistance that will emerge during therapy C. Clindamycin can be used if vancomycin is given concurrently D. The result means the organism is resistant to both clindamycin and erythromycin and requires IV vancomycin

Correct answer: B

Rationale: A positive D-zone test indicates inducible MLSB (macrolide-lincosamide-streptogramin B) resistance. The erm gene encodes methylase that, when induced by macrolide exposure, confers resistance to clindamycin as well. The organism appears susceptible on initial disk diffusion but will develop clinical resistance during clindamycin therapy. Using clindamycin in this scenario risks treatment failure. The sensitivity report notation “susceptible-inducible” is a laboratory flag that clindamycin should not be used. Answer A is incorrect — the D-zone test result overrides the apparent susceptibility on standard disk testing. Answer C is incorrect — adding vancomycin does not rescue the failed clindamycin. Answer D is incorrect — the organism is not necessarily resistant to all classes; TMP-SMX or doxycycline may be appropriate alternatives for a CA-MRSA skin infection; IV vancomycin is not always required for uncomplicated soft tissue infections.

Question 6

A nurse is conducting shift assessments. One patient is on contact precautions for MRSA. The patient develops a temperature of 38.9°C (102°F), a heart rate of 108 bpm, and reports new lower back pain. What is the nurse’s priority action?

A. Administer the scheduled PRN antipyretic and document the temperature B. Reassess in one hour — fever is expected with active MRSA infection C. Notify the provider immediately — new back pain with fever in an MRSA patient raises concern for vertebral osteomyelitis or epidural abscess D. Obtain blood cultures and administer the next dose of vancomycin before calling the provider

Correct answer: C

Rationale: New-onset back pain with fever in a patient with active MRSA bacteremia or MRSA infection represents a red flag for vertebral osteomyelitis or epidural abscess, both of which are serious complications requiring urgent evaluation (MRI, neurosurgical consultation). An untreated epidural abscess can cause irreversible spinal cord compression and paralysis within hours. The nursing priority is immediate provider notification so that urgent imaging can be ordered. Answer A is incorrect — treating the symptom without investigating the cause delays recognition of a potentially catastrophic complication. Answer B is incorrect — new back pain is not expected with uncomplicated MRSA and requires urgent assessment. Answer D is incorrect — obtaining blood cultures is appropriate, but drawing cultures and dosing antibiotics before provider notification may delay the MRI order that is most urgently needed; the first action is notification.

This reference is intended for nursing education purposes. Clinical decisions must be based on current institutional protocols, provider orders, and patient-specific factors. Antibiotic susceptibility patterns vary by region and institution — always confirm treatment with culture and sensitivity results.